Skip to content

Transdiagnostic Mechanisms in Fearful Avoidance

Transdiagnostic Mechanisms in Fearful Avoidance - The Brain in Avoidance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON52219
Enrollment
207
Registered
2021-05-12
Start date
2021-01-01
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety depression

Interventions

None listed

Sponsors

Radboud Universiteit Nijmegen
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Above 18 years of age • Fluent in Dutch • Eligible for MRI • Normal or corrected-to-normal vision • Normal uncorrected hearing • Willingness and ability to give written informed consent and willingness and ability to understand the nature and content, to participate and comply with the study requirements For patients: • Current or recent (i.e. last year) Axis I diagnosis of anxiety (Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia), PTSD or OCD and/or depression) Major Depressive Disorder, Persistent Depressive Disorder) diagnosis (assessed using the Mini-international Neuropsychiatric Interview)

Exclusion criteria

Exclusion criteria: • Insufficient comprehension of the Dutch language • Abnormal hearing or (uncorrected) vision • Drug or alcohol addiction in the past 6 months • Diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective illness • Current psychosis • Current neurological disorder, past neurological disorder within the last three months • Physical, cognitive, or intellectual impairments interfering with participation, such as deafness, blindness, or sensorimotor handicaps • History of cardiac disease

Design outcomes

Primary

MeasureTime frame
• Functional Magnetic Resonance Imaging (fMRI) • Psychophysiological recordings (heart rate, electromyography) • Behavioural measures of avoidance behaviour (choice: approach/avoid) • Self-report questionnaires (treatment outcome, avoidance questionnaire)

Secondary

MeasureTime frame
• Resting state fMRI • Electrodermal activity • Breathing rate • Questionnaires (anxiety symptoms, depressive symptoms, cognitive avoidance, intolerance of uncertainty, motivational systems)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)